Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:BHST NASDAQ:FATE NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$1.14+21.2%$0.59$0.30▼$10.62$135.41M2.0712.26 million shs4.09 million shsBHSTBioHarvest Sciences$12.50+13.2%$9.15$4.66▼$12.80$181.33M0.78108,302 shs164,007 shsFATEFate Therapeutics$1.39-15.0%$1.10$0.66▼$3.50$188.56M2.342.93 million shs2.34 million shsRANIRani Therapeutics$0.47+2.2%$0.51$0.39▼$3.75$32.93M-0.02303,949 shs576,532 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics+21.24%+11.76%+171.04%+169.69%-86.70%BHSTBioHarvest Sciences+13.22%+26.90%+41.88%+74.09%+1,249,999,900.00%FATEFate Therapeutics-14.98%-1.42%+44.33%+23.01%-55.02%RANIRani Therapeutics+2.25%-7.34%-6.22%+8.95%-76.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$1.14+21.2%$0.59$0.30▼$10.62$135.41M2.0712.26 million shs4.09 million shsBHSTBioHarvest Sciences$12.50+13.2%$9.15$4.66▼$12.80$181.33M0.78108,302 shs164,007 shsFATEFate Therapeutics$1.39-15.0%$1.10$0.66▼$3.50$188.56M2.342.93 million shs2.34 million shsRANIRani Therapeutics$0.47+2.2%$0.51$0.39▼$3.75$32.93M-0.02303,949 shs576,532 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics+21.24%+11.76%+171.04%+169.69%-86.70%BHSTBioHarvest Sciences+13.22%+26.90%+41.88%+74.09%+1,249,999,900.00%FATEFate Therapeutics-14.98%-1.42%+44.33%+23.01%-55.02%RANIRani Therapeutics+2.25%-7.34%-6.22%+8.95%-76.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.17Hold$4.13261.84% UpsideBHSTBioHarvest Sciences 2.50Moderate Buy$13.679.33% UpsideFATEFate Therapeutics 2.00Hold$3.30137.41% UpsideRANIRani Therapeutics 2.50Moderate Buy$7.331,465.28% UpsideCurrent Analyst Ratings BreakdownLatest RANI, BHST, APLT, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BHSTBioHarvest SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025FATEFate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RANIRani TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APLTApplied TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BHSTBioHarvest SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025FATEFate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RANIRani TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.50(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$460K356.89N/AN/A$0.49 per share2.33BHSTBioHarvest Sciences$25.19M8.15N/AN/A$0.08 per share156.25FATEFate Therapeutics$13.63M11.76N/AN/A$2.80 per share0.50RANIRani Therapeutics$1.03M32.69N/AN/A$0.06 per share7.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.45N/AN/AN/AN/A-354.24%-144.16%11/6/2025 (Estimated)BHSTBioHarvest Sciences-$12.91M-$0.70N/AN/AN/A-39.95%-11,357.84%-39.94%11/24/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)RANIRani Therapeutics-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%11/13/2025 (Estimated)Latest RANI, BHST, APLT, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025APLTApplied Therapeutics-$0.15N/AN/AN/AN/AN/A8/13/2025Q2 2025APLTApplied Therapeutics-$0.17-$0.15+$0.02-$0.15$0.42 millionN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/11/2025Q2 2025BHSTBioHarvest Sciences-$0.1075-$0.15-$0.0425-$0.24$8.53 million$8.52 million8/7/2025Q2 2025RANIRani Therapeutics-$0.19-$0.18+$0.01-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.941.94BHSTBioHarvest SciencesN/A0.600.36FATEFate TherapeuticsN/A8.048.04RANIRani TherapeuticsN/A0.540.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%BHSTBioHarvest SciencesN/AFATEFate Therapeutics97.54%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%BHSTBioHarvest SciencesN/AFATEFate Therapeutics5.51%RANIRani Therapeutics45.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30144.01 million141.71 millionOptionableBHSTBioHarvest SciencesN/A16.42 millionN/AN/AFATEFate Therapeutics550115.33 million108.98 millionOptionableRANIRani Therapeutics11071.87 million39.47 millionOptionableRANI, BHST, APLT, and FATE HeadlinesRecent News About These CompaniesBiotech Innovators Drive the Future of Next-Generation TherapeuticsSeptember 29, 2025 | msn.comBiotech Stocks Positioned to Transform Treatment With Next-Gen TherapeuticsSeptember 26, 2025 | financial-news.co.ukRani Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comRANI: Second Quarter Financial ResultsAugust 12, 2025 | finance.yahoo.comRani (RANI) Q2 Net Loss Improves 16%August 9, 2025 | theglobeandmail.comRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate UpdateAugust 7, 2025 | globenewswire.comRani Therapeutics Holdings, Inc. (RANI) - Yahoo FinanceJuly 18, 2025 | finance.yahoo.comRani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering AnnouncementJuly 15, 2025 | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingJuly 15, 2025 | globenewswire.comRani Therapeutics Shares Surge After ENDO 2025 Presentation AnnouncementJuly 14, 2025 | msn.comRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...July 14, 2025 | bakersfield.comBRani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 ConferenceJuly 14, 2025 | quiverquant.comQRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryJuly 14, 2025 | globenewswire.comGenelux Appoints Groen as General Counsel From Rani TherapeuticsJuly 8, 2025 | news.bloomberglaw.comNRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Investors Flock to Uranium as Nuclear Renaissance BuildsBy Jeffrey Neal Johnson | September 23, 2025Lithium Americas Rally Lifts Other Rare Earth Stocks By Gabriel Osorio-Mazilli | September 25, 2025Uranium Energy Stock Has Momentum—and More Upside AheadBy Gabriel Osorio-Mazilli | September 16, 2025RANI, BHST, APLT, and FATE Company DescriptionsApplied Therapeutics NASDAQ:APLT$1.14 +0.20 (+21.24%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$1.08 -0.05 (-4.82%) As of 10/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.BioHarvest Sciences NASDAQ:BHST$12.50 +1.46 (+13.22%) As of 10/13/2025 04:00 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Fate Therapeutics NASDAQ:FATE$1.39 -0.25 (-14.98%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$1.43 +0.04 (+2.95%) As of 10/13/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Rani Therapeutics NASDAQ:RANI$0.47 +0.01 (+2.25%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$0.49 +0.02 (+4.38%) As of 10/13/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
